On the mechanism of hepatocarcinogenesis of benzodiazepines: Evidence that diazepam and oxazepam are CYP2B inducers in rats, and both CYP2B and CYP4A inducers in mice

Drug Metabolism Reviews

Volumn 38, Issue 1-2, 2006, Pages 235-259

  Parkinson, Andrew ^a   Leonard, Neda ^a   Draper, Alison ^a   Ogilvie, Brian W ^a  

^a XenoTech LLC   (United States)

Author keywords

Benzodiazepines; CYP2B; CYP4A; Diazepam; Induction; Oxazepam; Phenobarbital; Tumor promotion

Indexed keywords

16ALPHA CYANOPREGNENOLONE; BENZODIAZEPINE DERIVATIVE; BETA NAPHTHOFLAVONE; CLOFIBRIC ACID; CYTOCHROME P450 2B; CYTOCHROME P450 4A; DIAZEPAM; ISONIAZID; OXAZEPAM; PHENOBARBITAL;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DOSE RESPONSE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INDUCTION; FEMALE; LIVER CARCINOGENESIS; MALE; NONHUMAN; RAT; SPECIES DIFFERENTIATION; TUMOR PROMOTION;

ALKANE 1-MONOOXYGENASE; ANIMALS; BENZODIAZEPINES; BLOTTING, WESTERN; BODY WEIGHT; CARCINOGENS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; HYPNOTICS AND SEDATIVES; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LAURIC ACIDS; LIVER NEOPLASMS; MALE; MICE; MICROSOMES, LIVER; NITROPHENOLS; ORGAN SIZE; OXAZEPAM; PHENOBARBITAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33646673623     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530600570081     Document Type: Article

References (50)

1. Arlotto, M. P., Greenway, D. J., Parkinson, A. (1989). Purification of two isozyme of rat liver microsomal cytochrome P-450 with testosterone 7α-hydroxylase activity. Arch. Biochem. Biophys. 270:441-457.
2. Balbi, A., Muscettalo, G., Staiano, N., Martire, G., De Lorenzo, F. (1980). Psychotropic drugs: evaluation of mutagenic effects. Pharmacol. Res. Commun. 12:423-432.
3. Berger, J. P., Akiyama, T. E., Meinke, P. T. (2005). PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26:244-251.
4. Bertagni, P., Marcucci, E. M., Mussini, E., Grattini, S. (1972). Biliary excretion of conjugated hydroxyl benzodiazepines after administration of several benzodiazepines to rats, guinea pigs and mice. J. Pharm. Sci. 61:965-966.
5. Bosgra, S., Mennes, W., Seinen, W. (2005). Proceedings in uncovering the mechanism behind peroxisome proliferator-induced hepatocarcinogenesis. Toxicology 206:309-323.
6. Bucher, J. R., Haseman, J. K., Herbert, R. A., Hejtmancik, M., Ryan, M. J. (1998). Toxicity and carcinogenicity studies of oxazepam in the Fischer 334 rat. Toxicol. Sci. 42:1-12.
7. Bucher, J. R., Shackleford, C. C., Haseman, J. K., Johnson, J. D., Kurtz, P. J., Persing, R. L. (1994). Carcinogenicity studies of oxazepam in mice. Fund. Appl. Toxicol. 23:280-297.
8. Burke, M. D., Mayer, R. T. (1974). Ethoxyresorufin: direct fluorimetric assay of microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab. Dispos. 2:583-588.
9. Clemmesen, J., Hjalgrim-Jensen, S. (1978). Is phenobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotoxicol. Environ. Supp. 1:457-470.
10. Cunningham, M. L., Maronpot, R. R., Thompson, M., Bucher, J. R. (1994). Early responses of the liver of B6C3F1 mice to the hepatocarcinogen oxazepam in mice. Toxicol. Appl. Pharmacol. 124:31-38.
11. de la Iglesia, A., Barsoum, N., Gough, A., Mitchell, A., Martin, R. A., di Fonzo, C., McGuire, E.J. (1981). Carcinogenesis bioassay of prazepam (Verstran) in rats and mice. Toxicol. Appl. Pharmacol. 57:39-54.
12. Devereux, T. R., White, C. M., Sills, R. C., Bucher, J. R., Maronpot, R. R., Anderson, M. W. (1994). Low frequency of H-ras mutations in hepatocellular adenomas and carcinomas and in hepatoblastomas from B6C3F1 mice exposed to oxazepam in the diet. Carcinogenesis 15:1083-1097.
13. Diwan, B. A., Rice, J. M., Ward, J. M. (1986). Tumor-promoting activity of benzodiazepine tranquilizers, diazepam and oxazepam, in mouse liver. Carcinogenesis 7:789-794.
14. Button, D. R., Parkinson, A. (1989). Reduction of 7-alkoxyresorufins by NADPH-cytochrome P450 reductase and its differential effects on their O-dealkylation by rat liver microsomal cytochrome P450. Arch. Biochem. Biophys. 268:617-629.
15. Fox, K. A., Lachen, R. B. (1974). Liver-cell adenomas and peliosis hepatitis in mice associated with oxazepam. Res. Commun. Chem. Pathol. Pharmacol. 8:481-488.
16. Grasso, P., Hinton, R. H. (1991). Evidence for and possible mechanisms of non-genotoxic Carcinogenesis in rodent liver. Mutat. Res. 248:271-290.
17. Grasso, P., Sharatt, M., Cohen, A. J. (1991). Role of persistent, nongenotoxic tissue damage in rodent cancer and relevance to humans. Ann. Rev. Pharmacol. Toxicol. 36:253-81.
18. Griffin, R. J., Burka, L. T. (1993). Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice. Drug Metab. Dispos. 21:918-926.
19. Griffin, R. J., Burka, L. T. (1994). Metabolism and elimination of oxazepam in F344 rats. Drug Metab. Dispos. 23:232-239.
20. Griffin, R. J., Burka, L. T., Cunningham, M. L. (1995). Activity of hepatic drug metabolizing enzymes following oxazepam feed treatment in B6C3F1 mice. Toxicol. Lett. 76:251-256.
21. Griffin, R. J., Dudley, C. N., Cunningham, M. L. (1996). Biochemical effects of the mouse hepatocarcinogen oxazepam: Similarities to phenobarbital. Fund. Appl. Toxicol. 29:147-154.
22. Harlow, B. L., Cramer, D. W. (1995). Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: Evidence from two combined case-control studies (Massachusetts, United States). Canc. Causes Control. 6:130-134.
23. Hino, O., Kitagawa, T. (1982). Effects of diazepam on hepatocarcinogenesis in the rat. Toxicol. Lett. 11:155-157.
24. Iida, M., Anna, C. H., Hartis, J., Bruno, M., Wetmore, B., Dubin, J. R., Sieber, S., Bennett, L., Cunningham, M. L., Paules, R. S., Tomer, K. B., Houle, C. D., Merrick, A. B., Sills, R. C., Devereux, T. R. (2003). Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 24:757-770.
25. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., Roberts, R. A., Fenner-Crisp, P. A. (2003). PPARα agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33:655-780.
26. Lai, D.Y. (2004). Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J. Environ. Sci. Health. C22:37-55.
27. Lehman-McKeeman, L. D., Caudill, D., Vassallo, J. D., Pearce, R. E., Madan, A., Parkinson, A. (1999). Effects of musk xylene and musk ketone on rat hepatic cytochrome P450 enzymes. Toxicol. Lett. 111:105-115.
28. Lu, A. Y. H., Levin, W. (1972). Partial purification of cytochrome P-450 and P-448 from rat liver microsomes. Biochem. Biophys. Res. Commun. 46:1334-1339.
29. Matsubara, T., Kioke, M., Touchi, A., Tochino, Y., Sugeno, K. (1976). Quantitative determination of cytochrome P-450 in rat liver homogenates. Anal. Biochem. 75:596-603.
30. McClain, R. M. (1995). Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. Prog. Clin. Biol. Res. 391:325-336.
31. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss Webster and B6C3F1 Mice (Feed Studies). (1993). Natl. Toxicol. Program Tech. Rep. Ser. 443:1-321.
32. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in F334/N Rats (Feed Studies). (1998). Natl. Toxicol. Program Tech. Rep. Ser. 468:1-189.
33. Olsen, J. H., Boice, J. D., Fraumeni, J. F. (1990). Cancer in children of epileptic mothers and the possible relation to maternal anticonvulsant therapy. Br. J. Cancer. 62:996-999.
34. Olsen, J. H., Boice, J. D., Jensen, J. P. A., Fraumeni, J. F. (1989). Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 81:803-808.
35. Olsen, J. H., Wallin, H., Boice, J. D., Rask, K., Schulgen, G., Fraumeni, J. F. (1993). Phenobarbital, drug metabolism and human cancer. Cancer Epidemol. 2:449-452.
36. Parkinson, A., Gemzik, B. (1991). Production and purification of antibodies against rat liver P-450 enzymes. Meth. Enzymol. 206:233-245.
37. Pedrick, M. S., Rumsby, P. C., Wright, V., Phillmore, H. E., Butler, W. H., Evans, J. G. (1994). Growth characterisitcs and Ha-ras mutations of cell cultures isolated from chemically induced mouse liver tumours. Carcinogenesis 15:1847-1852.
38. Preiss, A. M., Scheutwinkel-Reich, M., Fulle, I., Grohmann, H. G., Stan, H. J. (1982). Investigation with the salmonella/microsome test of psychopharmaceuticals used in meat production. Mutat. Res. 104:333-337.
39. Remandet, B., Gouy, D., Berthe, J., Mazue, G., Williams, G. M. (1984). Lack of initiating or promoting activity of six benzodiazepine tranquilizers in rat liver limited bioassay monitored by histopathology and assay of liver and plasma enzymes. Fund. Appl. Toxicol. 4:152-163.
40. Romano, M. C., Straub, K. M., Yodis, L. A. P., Eckardt, R. D., Newton, J. F. (1988). Anal. Biochem. 170:83-93.
41. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Strom, B. L., Harlap, S., Shapiro, S. (1995). Relation of benzodiazepine use to the risk of selected cancers: breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid and liver. Amer. J. Epidemiol. 141:1153-1160.
42. Shirts, S. B., Annegers, J. F., Hauser, W. A., Kurland, L. T. (1986). Cancer incidence in a cohort of patients with seizure disorders. J. Cancer. Inst. 77:83-87.
43. Singh, G., Driever, P. H., Sander, J. W. (2005). Cancer risk in people with epilepsy: the role of anti-epileptic drugs. Brain 128:7-17.
44. Sonderfan, A. J., Parkinson, A. (1988). Inhibition of steroid 5α-reductase and its effects on testosterone hydroxylation by rat liver microsomal P-450. Arch. Biochem. Biophys. 265:208-218.
45. Sonderfan, A. J., Arlotto, M. P., Dutton, D. R., McMillen, S. K., Parkinson, A. (1987). Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255:27-41.
46. Tierney, D. J., Haas, A. L., Koop, D. R. (1992). Degradation of cytochrome P-450 2E1: selective loss after labilization of the enzyme. Arch. Biochem. Biophys. 293:9-16.
47. Towbin, H., Staehelin, T., Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc. Natl. Acad. Sci. USA. 76:4350-4354.
48. Whysner, J., Ross, P. M., Williams, G. M. (1996). Phenobarbital mechanistic data and risk assessment: enzyme induction enhanced cell proliferation and tumor promotion. Pharmac. Ther. 71:153-191.
49. Williams, G. M., Iatropoulos, M. J. (2002). Alteration of liver cell function and proliferation: Differentiation between adaptation and toxicity. Toxicol. Pathol. 30:41-52.
50. 19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes. J. Biol. Chem. 258:8839-8847.